Regarding the relationship and value of CA-125 relative to other traditional biomarkers, CA-125 has emerged as a complementary biomarker in HF risk stratification [31], especially in the identification of systemic congestion, an aspect less well reflected by traditional markers such as NT-proBNP. The gene discussed is NPPB; the disease is hydrops fetalis.